Training of Ugandans in Basic and Translational Research on TB and Emerging Infectious Diseases

对乌干达人进行结核病和新发传染病基础和转化研究培训

• 批准号: 10341224
• 负责人: Jerrold J. Ellner
• 金额: $ 26.46万
• 依托单位: RBHS-NEW JERSEY MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-03-12 至 2023-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10341224
• 关键词: Address; Area; Basic Science; Boston; British; Centers for Disease Control and Prevention (U.S.); Clinical Trials; Coupled; Developing Countries; Development; Doctor of Philosophy; Drug resistance; Emerging Communicable Diseases; Enrollment; European; Evaluation; Extramural Activities; Faculty; Fogarty International Center; Foundations; Funding; Future; Immunity; Immunology; Infectious Diseases Research; Institution; Joints; Knowledge; Laboratories; Link; Medical Research; Medical center; Mentorship; Molecular; New Jersey; Pathogenesis; Pharmacotherapy; Regimen; Research; Research Design; Research Infrastructure; Research Project Summaries; Scientist; Secure; Site; Training; Training Programs; Translational Research; Treatment Protocols; Trust; Uganda; United States National Institutes of Health; Universities; base; clinical epidemiology; doctoral student; laboratory experience; medical schools; member; novel diagnostics; programs; recruit; skills; training opportunity; translational study; vaccine trial

PROJECT SUMMARY The research infrastructure in Uganda has expanded considerably in the last decade and Makerere University (MU) in Kampala has become one of the principal academic institutions worldwide for collaborative research on TB and emerging infectious diseases. Currently NIH, CDC, Gates Foundation, Wellcome Trust, British Medical Research Council and the European & Developing Countries Clinical Trials Partnership provide substantial support for TB and other infectious diseases research in Uganda, including evaluation of new diagnostics; drug treatment regimens; and vaccines and translational studies of pathogenesis and correlates of immunity. As such, most of the training is in clinical epidemiology and study design and none specifically targets the gap in laboratory-based research scientists that will become faculty members, competitive for extramurally funded research programs. Because of identified gaps in training in basic and translational research on TB and emerging infectious diseases, Boston Medical Center (BMC)/Boston University School of Medicine (BUSM) sought out and secured funding from the Fogarty International Center to fund capacity building in this area. During this period, three Ugandan scientists received training under the program and are currently pursuing further graduate studies. The program established collaborative links and solidified a joint commitment to co-mentorship of Uganda trainees by BMC/BUSM and MU. Short courses funded under this program have become essential to the training regimen of masters and PhD students and have provided a conduit for discussion with faculty and further recruitment. Despite these strides, there is still a pressing need to continue to expand training opportunities in basic and translational research. For this renewal application, we will make two significant changes. First, we will target medical school graduates who intend to enroll in a PhD program at MU; trainees will be recruited to one or two areas designated as critical for development by the MU faculty and the Program Directors and Scientific Directors. Second, Rutgers-New Jersey Medical School (NJMS) has been added as a second site of training. Its addition will provide expertise molecular mechanisms of drug resistance and basic and translational immunology. Above all, our main objective of the program will be to provide trainees with a strong background in basic research skills and knowledge through rigorous targeted coursework coupled with intensive laboratory training in a particular research area. Our training program is tailored to address the current and future TB and emerging infectious disease research needs of MU as well as Uganda as a whole.

项目概要 乌干达的研究基础设施在过去十年中得到了显着扩展，马凯雷雷 坎帕拉大学 (MU) 已成为全球合作的主要学术机构之一 结核病和新发传染病的研究。目前 NIH、CDC、盖茨基金会、Wellcome Trust、 英国医学研究委员会和欧洲及发展中国家临床试验合作伙伴提供 为乌干达的结核病和其他传染病研究提供大力支持，包括评估新的 诊断；药物治疗方案；疫苗以及发病机制及其相关性的转化研究 免疫。因此，大部分培训都是临床流行病学和研究设计方面的，没有专门的培训 目标是缩小实验室研究科学家的差距，这些科学家将成为教职人员，具有竞争力 校外资助的研究项目。由于基础培训和转化培训方面已发现差距 结核病和新发传染病研究，波士顿医学中心 (BMC)/波士顿大学医学院 医学 (BUSM) 向福格蒂国际中心寻求并获得资金来资助能力 该地区的建筑。在此期间，三名乌干达科学家接受了该计划的培训，并在 目前正在攻读研究生学位。该计划建立了合作联系并巩固了联合 承诺由 BMC/BUSM 和 MU 共同指导乌干达学员。在此资助的短期课程 计划已成为硕士和博士生培训方案的重要组成部分，并提供了 与教师讨论和进一步招聘的渠道。尽管取得了这些进步，但仍然存在迫切需要 继续扩大基础研究和转化研究的培训机会。对于本次续签申请， 我们将做出两项重大改变。首先，我们将针对打算入读医学院的医学院毕业生 密苏里大学博士课程；受训人员将被招募到被指定为对发展至关重要的一两个领域 密苏里大学教职人员、项目主任和科学主任。二、罗格斯-新泽西医学 学校 (NJMS) 已被添加为第二个培训地点。它的加入将提供分子专业知识 耐药机制以及基础和转化免疫学。最重要的是，我们的主要目标 计划将通过以下方式为学员提供基础研究技能和知识的强大背景 严格的有针对性的课程作业以及特定研究领域的强化实验室培训。我们的 培训计划专为解决当前和未来的结核病和新发传染病研究而定制 MU 以及整个乌干达的需求。